Neurimmune joins ACCESS-AD consortium, an innovative health initiative to accelerate timely and equitable AD diagnosis, treatment and care

Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium – bringing together academic institutions, industry partners, SMEs and patient organisations – is a five-year programme, co-led by Amsterdam UMC, Siemens Healthineers, King’s College London and Gates Ventures, with funding from the European Commission’s Innovative Health Initiative.

Neurimmune is pleased to join the newly established consortium in support of the development of advanced imaging and blood-based digital biomarkers. These efforts are intended to improve diagnostic precision, enable patient stratification, and establish a foundation for the development of next-generation disease-modifying therapies in Alzheimer’s disease.

ACCESS-AD receives funding under the auspices of the Innovative Health Initiative Joint Undertaking (IHI JU). For more information, please visit http://www.access-ad.org.

About Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-NogoA antibody NG004 (Phase 1) for spinal cord injury and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.